Eton Pharmaceuticals, Inc. Accounts Receivable, Sale
Eton Pharmaceuticals, Inc. (ETON) reported Accounts Receivable, Sale of $5.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-16.
Discontinued › Notes
us-gaap:AccountsReceivableSale · last filed 2022-03-16
- Eton Pharmaceuticals, Inc. accounts receivable, sale for fiscal 2021 was $5.00M.
| Period end | Accounts Receivable, Sale 12 month |
|---|---|
| 2021-12-31 | $5.00M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |